# US 2015/0307866 A1 · Novel Asparaginase and Treating Diseases Associated With Asparagine Dependence

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0307866 A1
- Document ID: US20150307866A1
- Status: Published application
- Kind: A1
- Application number: 14/706,132
- Filed: 2015-05-07
- Published: 2015-10-29
- Earliest claimed: 2011-10-10
- Assignees: Children's Hospital Los Angeles
- Applicants: Children's Hospital Los Angeles
- Inventors: Donald L. Durden
- Web page: https://patentgrep.com/patent/US20150307866A1

## CPC

- C12N 9/82: Asparaginase {(3.5.1.1)}
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- C12Y 305/01001: Asparaginase (3.5.1.1)
- C07K 2319/034: containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
- C07K 2319/21: containing a His-tag
- C07K 2319/23: containing a GST-tag
- C07K 2319/42: containing a HA(hemagglutinin)-tag
- C07K 2319/43: containing a FLAG-tag
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.

## Claims

### Claim 1

An isolated and/or recombinantly produced polypeptide comprising of an amino acid sequence that corresponds to the protein having SEQ ID NO: 10 and has an amino acid residue other than proline at amino acid position 121, and optionally a signal sequence linked to its N-terminus.

### Claim 2 (depends on 1)

The isolated and/or recombinantly produced polypeptide of claim 1, wherein the polypeptide has an amino acid sequence that has at least 90-100%, 91-100%, 92-100%, 93-100%, 94-100%, 95-100%, 96-100%, 97-100%, 98-100%, 99-100%, or 100% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

### Claim 3 (depends on 1)

The isolated and/or recombinantly produced polypeptide of claim 1, wherein the signal sequence is SEQ ID NO: 5 or SEQ ID NO: 6.

### Claim 4 (depends on 1)

The isolated and/or recombinantly produced polypeptide of claim 1, wherein the amino acid residue is serine, alanine, glycine, cysteine, or threonine, preferably serine.

### Claim 5 (depends on 1)

The isolated and/or recombinantly produced polypeptide of claim 1, wherein the polypeptide exhibits no glutaminase activity or reduced glutaminase activity as compared to a protein having SEQ ID NO: 10.

### Claim 6 (depends on 1)

The isolated and/or recombinantly produced polypeptide of claim 1, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is greater than about 7.5, preferably 7.6 to about 21.8, times that of its kinetic rate of glutaminase activity, or a kinetic rate of asparaginase activity that is between 7.5 to 22 times that of its kinetic rate of glutaminase activity.

### Claim 7 (depends on 1)

An isolated nucleic acid molecule which encodes the polypeptide of claim 1.

### Claim 8 (depends on 7)

A host cell which contains the isolated nucleic acid molecule of claim 7.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising as an active pharmaceutical ingredient, the polypeptide according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the polypeptide is provided in a therapeutically effective amount for treating a disease which responds to asparagine depletion and/or asparaginase therapy.

### Claim 11 (depends on 1)

A method of treating a patient having a disease which responds to asparagine depletion and/or asparaginase therapy which comprises
administering to the patient an isolated and/or recombinantly produced polypeptide according to claim 1.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the amount of the polypeptide administered to the patient is a therapeutically effective amount.

### Claim 13 (depends on 1)

Use of a polypeptide according to claim 1 for the treatment of disease which responds to asparagine depletion and/or asparaginase therapy.

### Claim 14 (depends on 1)

Use of a polypeptide according to claim 1 for the preparation of a medicament for the treatment of a disease which responds to asparagine depletion and/or asparaginase therapy.

### Claim 15 (depends on 1)

A kit which comprises at least one polypeptide according to claim 1 packaged together with a drug delivery service.

### Claim 16 (depends on 1)

An expression vector which comprises a nucleic acid sequence that encodes the polypeptide according to claim 1.
